METHOD OF UNDERLYING DISEASE EARLY RELAPSE DEVELOPMENT PREDICTION FOLLOWING AUTOLOGOUS TRANSPLANTATION OF PERIPHERAL STEM HAEMOPOIETIC CELLS IN PATIENTS SUFFERING FROM HAEMOBLASTOSIS Russian patent published in 2008 - IPC A61K48/00 G01N33/53 

FIELD: medicine.

SUBSTANCE: method provides creation of method of underlying disease early relapse development prediction following autologous transplantation of peripheral stem haemopoietic cells (ATPSHC) at stages of patient preparation to transplantation. Complex immune status indicators in patients suffering from haemoblastosis considering their diagnostic informativity within the period previous ATPSHC. They include: relative number of CD4⁺-cells in S, G2/M cycling state 17.7% to 21.4% (DF =+6.2), a ≥21.4 % (DF= +10.2); relative number of CD4⁺-cages in apoptosis, ≤ 0.8 % (DF=-7.2); relative number of CD4⁺- memory cells ≤11,1 % (DF= +8.1); relative number of CD8 ⁺ - memory cells ≥ 9.41% (DF= +5.3); migration inhibition index (MII) for PHA stimulation is 0.3 st.units (DF= +7.8), a ≥0.37 st.units (DF=-5.6); effector function indicator (EFE) for PHA stimulation is ≤2.24 st.units (DF =-7.3); "ИРИ" ≤0.45 st.units (DF= +6.3), IgM concentration in blood serum ≤0.59 g/l (DF= +3.8); HLA-DR molecules expression level on monocytes ≥0.5 st.units (DF=-5.1) and absolute number of CD16⁺-cells to ATPSHC ≥151 kl/mkl (DF=-2.5). At total amount of positive diagnostic factors (∑DF= +13 and more) early relapse development following ATPSHC is predicted, and total amount of negative diagnostic factors (∑DF=-17 and less) indicates predictable favourable outcome of transplantation.

EFFECT: higher accuracy of prediction procedure.

2 ex